



PB 121 of 2024

National Health (Minimum Stockholding) Amendment Determination (No. 10) 2024

I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 29 October 2024

Nikolai Tsyganov
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1 Name	1
2 Commencement.....	1
3 Authority	1
4 Schedules.....	1
Schedule 1—Amendments commencing 1 November 2024	2
<i>National Health (Minimum Stockholding) Determination 2023</i>	2
Schedule 2— Amendments commencing 1 April 2025	12
<i>National Health (Minimum Stockholding) Determination 2023</i>	12

1 Name

- (1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 10) 2024*.
- (2) This instrument may also be cited as PB 121 of 2024.

2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table	1 November 2024.	1 November 2024
2. Schedule 1	1 November 2024.	1 November 2024
3. Schedule 2	1 April 2025.	1 April 2025

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing 1 November 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Omit:

Amiodarone	Tablet containing amiodarone hydrochloride 200 mg	Oral	APO-Amiodarone	between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand
------------	---	------	----------------	--

2 Schedule 1 (table)

Omit:

Amitriptyline	Tablet containing amitriptyline hydrochloride 10 mg	Oral	APO-Amitriptyline 10	between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand
---------------	---	------	----------------------	--

3 Schedule 1 (table)

Omit:

Amitriptyline	Tablet containing amitriptyline hydrochloride 25 mg	Oral	APO-Amitriptyline 25	between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand
---------------	---	------	----------------------	--

4 Schedule 1 (table)

Omit:

Amitriptyline	Tablet containing amitriptyline hydrochloride 50 mg	Oral	APO-Amitriptyline 50	between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand
---------------	---	------	----------------------	--

5 Schedule 1 (table)

Omit:

Atenolol	Tablet 50 mg	Oral	APO-Atenolol	between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand
----------	--------------	------	--------------	--

6 Schedule 1 (table)

Omit:

Bosentan	Tablet 125 mg (as monohydrate)	Oral	BOSLEER	between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand
Bosentan	Tablet 62.5 mg (as monohydrate)	Oral	BOSLEER	between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand
Bosentan	Tablet 62.5 mg (as monohydrate)	Oral	Tracleer	between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand

7 Schedule 1 (table)

Omit:

Calcitriol	Capsule 0.25 microgram	Oral	APO-Calcitriol	between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand
Calcitriol	Capsule 0.25 microgram	Oral	Kosteo	between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand

8 Schedule 1 (table)

After:

Ceftriaxone	Powder for injection 2 g (as sodium)	Injection	Ceftriaxone Viatris	after 31 May 2024—6 months stock by reference to usual demand of both Ceftriaxone Viatris and Ceftriaxone Alphapharm added together
Celecoxib	insert: Capsule 100 mg	Oral	NOUMED CELECOXIB	between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand
Celecoxib	Capsule 200 mg	Oral	NOUMED CELECOXIB	between 1 November 2024 and 31 December 2024—0 months stock by

reference to usual demand

9 Schedule 1 (table)

Omit:

Ciprofloxacin	Tablet 250 mg (as hydrochloride)	Oral	APX-Ciprofloxacin	between 1 October 2024 and 31 October 2024—0 months stock by reference to usual demand
Ciprofloxacin	Tablet 500 mg (as hydrochloride)	Oral	APX-Ciprofloxacin	between 1 October 2024 and 31 October 2024—0 months stock by reference to usual demand
Ciprofloxacin	Tablet 750 mg (as hydrochloride)	Oral	APX-Ciprofloxacin	between 1 October 2024 and 31 October 2024—0 months stock by reference to usual demand

10 Schedule 1 (table)

Omit:

Diazepam	Tablet 2 mg	Oral	APO-Diazepam	between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand
Diazepam	Tablet 5 mg	Oral	APO-Diazepam	between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand
Diclofenac	Tablet (enteric coated) containing diclofenac sodium 25 mg	Oral	APO-Diclofenac	between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand
Diclofenac	Tablet (enteric coated) containing diclofenac sodium 50 mg	Oral	APO-Diclofenac	between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand

11 Schedule 1 (table)

	After:				
Doxycycline	Tablet 50 mg (as hyclate)	Oral	Doxsig		4 months stock by reference to usual demand
	insert:				
Duloxetine	Capsule 30 mg (as hydrochloride)	Oral	Cymbalta		between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand
Duloxetine	Capsule 60 mg (as hydrochloride)	Oral	Cymbalta		between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand

12 Schedule 1 (table)

	Omit:				
Entecavir	Tablet 0.5 mg (as monohydrate)	Oral	ENTECLUDE		between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand
Entecavir	Tablet 1 mg (as monohydrate)	Oral	ENTECLUDE		between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand

13 Schedule 1 (table)

	After:				
Fluconazole	Powder for oral suspension 50 mg in 5 mL, 35 mL	Oral	Diflucan		4 months stock by reference to usual PBS demand
	insert:				
Fluoxetine	Capsule 20 mg (as hydrochloride)	Oral	Prozac 20		between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand

14 Schedule 1 (table)

	Omit:				
Furosemide	Oral solution 10 mg per mL, 30 mL	Oral	Lasix		4 months stock by reference to usual PBS demand
	substitute:				
Furosemide	Oral solution 10 mg per ml, 30 ml	Oral	Lasix		(a) between 1 November 2024 and 31 March 2024—4 months stock by reference to usual PBS demand (b) after 31 March 2024—6 months stock by reference to usual PBS demand

15 Schedule 1 (table)

	Omit:				
Ibuprofen	Tablet 400 mg	Oral	MEDICHOICE IBUPROFEN 400 mg		between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand

16 Schedule 1 (table)

	After:				
Insect allergen extract-yellow jacket venom	Injection set containing 550 micrograms with diluent	Injection	Hymenoptera Yellow Jacket Venom		6 months stock by reference to usual PBS demand
	insert:				
Irbesartan	Tablet 150 mg	Oral	Irbesartan GH		between 1 November 2024 and 28 February 2025—0 months stock by reference to usual demand
Irbesartan	Tablet 300 mg	Oral	Irbesartan GH		between 1 November 2024 and 28 February 2025—0 months stock by reference to usual demand

17 Schedule 1 (table)

Omit:

Irbesartan	Tablet 75 mg	Oral	Karvea	between 1 October 2024 and 31 October 2024—0 months stock by reference to usual demand
------------	--------------	------	--------	--

18 Schedule 1 (table)

Omit:

Itraconazole	Capsule 100 mg	Oral	APO-Itraconazole	between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand
--------------	----------------	------	------------------	--

19 Schedule 1 (table)

After:

Labetalol	Tablet containing labetalol hydrochloride 100 mg	Oral	Presolol 100	between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand
-----------	--	------	--------------	--

insert:

Lamotrigine	Tablet 100 mg	Oral	NOUMED LAMOTRIGINE	between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand
Lamotrigine	Tablet 200 mg	Oral	NOUMED LAMOTRIGINE	between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand
Lamotrigine	Tablet 25 mg	Oral	NOUMED LAMOTRIGINE	between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand
Lamotrigine	Tablet 50 mg	Oral	NOUMED LAMOTRIGINE	between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand
Lansoprazole	Capsule 30 mg	Oral	NOUMED LANSOPRAZOLE	between 1 November 2024 and 31 December 2024—0 months stock by

				reference to usual demand
20 Schedule 1 (table)				
Omit:				
Macrogol 3350	Sachets containing powder for oral solution 13.125 g with electrolytes, 30	Oral	Movicol	between 1 October 2024 and 31 October 2024—0 months stock by reference to usual demand
21 Schedule 1 (table)				
Omit:				
Nifedipine	Tablet 30 mg (controlled release)	Oral	Addos XR 30	between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand
Nifedipine	Tablet 60 mg (controlled release)	Oral	Addos XR 60	between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand
22 Schedule 1 (table)				
Omit:				
Pioglitazone	Tablet 15 mg (as hydrochloride)	Oral	Acpio 15	between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand
Pioglitazone	Tablet 30 mg (as hydrochloride)	Oral	Acpio 30	between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand
Pioglitazone	Tablet 45 mg (as hydrochloride)	Oral	Acpio 45	between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand
23 Schedule 1 (table)				
After:				
Pregabalin	Capsule 150 mg	Oral	Cipla Pregabalin	between 1 October 2024 and 28 February 2025—0 months stock by reference to usual demand
insert:				
Pregabalin	Capsule 150 mg	Oral	NOUMED PREGABALIN	between 1 November 2024 and 31

				December 2024—0 months stock by reference to usual demand
Pregabalin	Capsule 25 mg	Oral	NOUMED PREGABALIN	between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand
Pregabalin	Capsule 300 mg	Oral	NOUMED PREGABALIN	between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand
Pregabalin	Capsule 75 mg	Oral	NOUMED PREGABALIN	between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand

24 Schedule 1 (table)

Omit:

Riluzole	Tablet 50 mg	Oral	APO-Riluzole	between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand
----------	--------------	------	--------------	--

25 Schedule 1 (table)

After:

Salbutamol	Nebuliser solution 5 mg (as sulfate) in 2.5 ml single dose units, 30	Inhalation	Salbutamol Cipla	between 1 June 2024 and 30 November 2024—4 months stock by reference to usual demand.
------------	--	------------	------------------	---

insert:

Sertraline	Tablet 100 mg (as hydrochloride)	Oral	NOUMED SERTRALINE	between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand
Sertraline	Tablet 50 mg (as hydrochloride)	Oral	NOUMED SERTRALINE	between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand
Simvastatin	Tablet 10 mg	Oral	NOUMED SIMVASTATIN	between 1 November 2024 and 31 December 2024—0

				months stock by reference to usual demand
Simvastatin	Tablet 20 mg	Oral	NOUMED SIMVASTATIN	between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand
Simvastatin	Tablet 40 mg	Oral	NOUMED SIMVASTATIN	between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand

26 Schedule 1 (table)

	After:			
Tacrolimus	Capsule 5 mg	Oral	Tacrograf	3 months stock by reference to usual demand
	insert:			
Telmisartan	Tablet 80 mg	Oral	NOUMED TELMISARTAN	between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand

27 Schedule 1 (table)

	After:			
Temazepam	Tablet 10 mg	Oral	APO-Temazepam	2.5 months stock by reference to usual demand
	insert:			
Tenofovir	Tablet containing tenofovir disoproxil maleate 300 mg	Oral	Tenofovir Disoproxil Viartis	after 31 January 2025— 4 months stock by reference to usual demand of both Tenofovir Disoproxil Viartis and Tenofovir Disoproxil Mylan added together

28 Schedule 1 (table)

	Omit:			
Valaciclovir	Tablet 500 mg (as hydrochloride)	Oral	Valaciclovir generichealth	between 1 August 2024 and 31 October 2024—0 months stock by reference to usual demand

29 Schedule 1 (table)

Valproic acid	After: Tablet, crushable, containing sodium valproate 100 mg	Oral	Epilim	4 months stock by reference to usual PBS demand
Vancomycin	insert: Powder for injection 1 g (1,000,000 I.U.) (as hydrochloride)	Injection	Vancomycin Viartis	after 31 November 2024— 4 months stock by reference to usual demand of both Vancomycin Viartis and Vancomycin Alphapharm added together
Vancomycin	Powder for injection 500 mg (500,000 I.U.) (as hydrochloride)	Injection	Vancomycin Viartis	after 31 November 2024— 4 months stock by reference to usual demand of both Vancomycin Viartis and Vancomycin Alphapharm added together

Schedule 2— Amendments commencing 1 April 2025

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

	After:				
Atomoxetine	Capsule 80 mg (as hydrochloride)	Oral	APO-Atomoxetine	3 months stock by reference to usual demand	
	insert:				
Atropine	Injection containing atropine sulfate monohydrate 600 micrograms in 1 mL	Injection	Atropine Injection (Pfizer)	6 months stock by reference to usual PBS demand	

2 Schedule 1 (table)

	After:				
Baclofen	Tablet 10 mg	Oral	APO-Baclofen	3 months stock by reference to usual demand	
	insert:				
Balsalazide	Capsule containing balsalazide sodium 750 mg	Oral	Colazide	6 months stock by reference to usual PBS demand	

3 Schedule 1 (table)

	After:				
Budesonide	Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses	Inhalation by Mouth	Pulmicort Turbuhaler	6 months stock by reference to usual PBS demand	
	insert:				
Calcium	Tablet 600 mg (as carbonate)	Oral	Calci-Tab 600	6 months stock by reference to usual PBS demand	

4 Schedule 1 (table)

	After:				
Fentanyl	Transdermal patch 8.4 mg	Transdermal	APO-Fentanyl	3 months stock by reference to usual demand	
	insert:				
Ferrous Sulfate	Oral liquid containing 30 mg ferrous sulfate heptahydrate per mL, 250 mL	Oral	Ferro-Liquid	6 months stock by reference to usual PBS demand	

5 Schedule 1 (table)

After:

Glucose and ketone indicator-urine	Test strips, 50 (Keto-Diastix)	For External Use	Keto-Diastix	4 months stock by reference to usual PBS demand
------------------------------------	--------------------------------	------------------	--------------	---

insert:

Glyceryl trinitrate	Sublingual spray (pump pack) 400 micrograms per dose, 200 doses	Sublingual	Nitrolingual Pumpspray	6 months stock by reference to usual PBS demand
---------------------	---	------------	------------------------	---

6 Schedule 1 (table)

After:

Triglycerides - medium chain, formula	Oral powder 400 g (Lipistart)	Oral	Lipistart	0 months stock by reference to usual PBS demand
---------------------------------------	-------------------------------	------	-----------	---

insert:

Triglycerides, medium chain	Oil 500 ml (MCT Oil)	Oral	MCT Oil	6 months stock by reference to usual PBS demand
-----------------------------	----------------------	------	---------	---